• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.

作者信息

Frishman W H, Eisen G, Charlap S, Strom J A

机构信息

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.

出版信息

J Clin Hypertens. 1987 Dec;3(4):605-9.

PMID:3134517
Abstract

The long-term safety and efficacy of twice-daily sustained-release verapamil were assessed compared to thrice-daily immediate-release verapamil in 25 patients with mild to moderate systemic hypertension. Patients were monitored on immediate-release verapamil (480 mg/day) for 6 months and were then placed on twice-daily sustained-release verapamil for an additional 6 months. Immediate-release verapamil, with and without a diuretic, successfully controlled standing and sitting systolic and diastolic blood pressures (p less than 0.001) compared to pretreatment baseline values. The effects of verapamil on blood pressure were sustained for an additional 6 months when the sustained-release formulation was utilized. Both formulations were well tolerated, with no significant effects on heart rate. In conclusion, verapamil, in both the immediate- and sustained-release formulations, is equally effective in lowering blood pressure for up to 1 year.

摘要

相似文献

1
Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.
J Clin Hypertens. 1987 Dec;3(4):605-9.
2
A new sustained-release formulation of verapamil in the treatment of hypertension.维拉帕米新的缓释制剂用于治疗高血压。
J Clin Hypertens. 1986 Sep;2(3 Suppl):125S-132S.
3
Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.从缓释型钙通道阻滞剂转换为速释型钙通道阻滞剂:轻至中度高血压患者的转归
Clin Ther. 1993 Nov-Dec;15(6):1002-10.
4
Antihypertensive efficacy of sustained-release verapamil.缓释维拉帕米的降压疗效
J Clin Hypertens. 1987 Dec;3(4):536-46.
5
Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension.依那普利与缓释维拉帕米治疗老年轻至中度原发性高血压的疗效及耐受性
Clin Ther. 1990 Mar-Apr;12(2):139-48.
6
Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension.缓释维拉帕米和长效普萘洛尔:治疗轻至中度高血压的疗效及副作用比较
J Hum Hypertens. 1988 Mar;1(4):305-10.
7
Twice-daily administration of oral verapamil in the treatment of essential hypertension.每日两次口服维拉帕米治疗原发性高血压。
Arch Intern Med. 1986 Mar;146(3):561-5.
8
Comparisons of verapamil administration twice and three times daily in hypertension.高血压患者中维拉帕米每日两次与每日三次给药的比较。
Ann Clin Res. 1988;20(3):195-200.
9
[Comparison of the efficacy and tolerability of sustained-release verapamil and captopril in mild to moderate essential arterial hypertension].缓释维拉帕米与卡托普利治疗轻至中度原发性高血压的疗效及耐受性比较
Ann Cardiol Angeiol (Paris). 1991 Oct;40(8):509-13.
10
Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension.硝苯地平每日两次作为轻度原发性高血压二级治疗药物的双盲、安慰剂对照试验。
J Clin Hypertens. 1987 Dec;3(4):579-88.

引用本文的文献

1
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.维拉帕米。对其药效学和药代动力学特性以及在高血压治疗中的应用的最新综述。
Drugs. 1989 Jul;38(1):19-76. doi: 10.2165/00003495-198938010-00003.